215 related articles for article (PubMed ID: 36300627)
21. Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
Yang YC; Banuelos CA; Mawji NR; Wang J; Kato M; Haile S; McEwan IJ; Plymate S; Sadar MD
Clin Cancer Res; 2016 Sep; 22(17):4466-77. PubMed ID: 27140928
[TBL] [Abstract][Full Text] [Related]
22. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
23. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
[TBL] [Abstract][Full Text] [Related]
24. Cooperation between Polycomb and androgen receptor during oncogenic transformation.
Zhao JC; Yu J; Runkle C; Wu L; Hu M; Wu D; Liu JS; Wang Q; Qin ZS; Yu J
Genome Res; 2012 Feb; 22(2):322-31. PubMed ID: 22179855
[TBL] [Abstract][Full Text] [Related]
25. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
Rizzo A; Mollica V; Rosellini M; Marchetti A; Ricci AD; Fiorentino M; Battelli N; Santoni M; Massari F
Pathol Res Pract; 2021 Jun; 222():153440. PubMed ID: 33857854
[TBL] [Abstract][Full Text] [Related]
26. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
[TBL] [Abstract][Full Text] [Related]
27. Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer.
Fong KW; Zhao JC; Kim J; Li S; Yang YA; Song B; Rittie L; Hu M; Yang X; Perbal B; Yu J
Cancer Res; 2017 Jan; 77(2):412-422. PubMed ID: 27815387
[TBL] [Abstract][Full Text] [Related]
28. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
[TBL] [Abstract][Full Text] [Related]
29. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
Krause WC; Shafi AA; Nakka M; Weigel NL
Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
[TBL] [Abstract][Full Text] [Related]
31. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
Peacock SO; Fahrenholtz CD; Burnstein KL
Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
[TBL] [Abstract][Full Text] [Related]
32. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
Yi Q; Han X; Yu HG; Chen HY; Qiu D; Su J; Lin R; Batist G; Wu JH
Oncogene; 2024 May; 43(20):1522-1533. PubMed ID: 38532114
[TBL] [Abstract][Full Text] [Related]
33. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer.
Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Urano T; Takahashi S; Homma Y; Aburatani H; Inoue S
Oncotarget; 2015 Feb; 6(4):2263-76. PubMed ID: 25537508
[TBL] [Abstract][Full Text] [Related]
34. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
35. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
36. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
[TBL] [Abstract][Full Text] [Related]
37. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
38. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy.
Lee GT; Nagaya N; Desantis J; Madura K; Sabaawy HE; Kim WJ; Vaz RJ; Cruciani G; Kim IY
Mol Cancer Ther; 2021 Mar; 20(3):490-499. PubMed ID: 33277442
[TBL] [Abstract][Full Text] [Related]
39. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
[No Abstract] [Full Text] [Related]
40. De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted peptide PROTAC for Prostate Cancer Therapy.
Ma B; Fan Y; Zhang D; Wei Y; Jian Y; Liu D; Wang Z; Gao Y; Ma J; Chen Y; Xu S; Li L
Adv Sci (Weinh); 2022 Oct; 9(28):e2201859. PubMed ID: 35971165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]